A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study

被引：1

作者：

Giovannoni, Gavin ^{[1
]}

Boyko, Alexey ^{[2
]}

Correale, Jorge ^{[3
]}

Edan, Gilles ^{[4
]}

Freedman, Mark S. ^{[5
,6
]}

Montalban, Xavier ^{[7
]}

Rammohan, Kottil ^{[8
]}

Stefoski, Dusan ^{[9
]}

Yamout, Bassem ^{[10
,11
]}

Leist, Thomas

Aydemir, Aida ^{[12
]}

Borsi, Laszlo

di Cantogno, Elisabetta Verdun ^{[12
]}

机构：

[1] Queen Mary Univ London, Blizard Inst, Barts & London Sch Med & Dent, London, England

[2] Pirogov Russian Natl Res Med Univ, Fed Ctr Brain Res & Neurotechnol, Dept Neurol Neurosurg & Med Genet, Moscow, Russia

[3] FLENI Inst, Dept Neurol, Buenos Aires, Argentina

[4] Univ Hosp Rennes, Dept Neurol, Rennes, France

[5] Univ Ottawa, Dept Med, Ottawa, ON, Canada

[6] Ottawa Hosp Res Inst, Ottawa, ON, Canada

[7] Hosp Univ Vall Hebron, Ctr Esclerosi Multiple Catalunya Cemcat, Dept Neurol Neuroimmunol, Barcelona, Spain

[8] Univ Miami, MS Res Ctr, Sch Med, Miami, FL USA

[9] Rush Med Coll, Dept Neurol Sci, Chicago, IL USA

[10] Harley St Med Ctr, Neurol Inst, Abu Dhabi, U Arab Emirates

[11] Amer Univ, Beirut Med Ctr, Beirut, Lebanon

[12] Merck KGaA, Darmstadt, Germany

来源：

NEURODEGENERATIVE DISEASE MANAGEMENT | 2023年 / 13卷 / 05期

关键词：

D O I：

10.2217/nmt-2023-0018

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

What is this summary about? Previous studies have shown that people living with multiple sclerosis ( MS) treated with cladribine tablets have fewer relapses (where new symptoms occur or existing symptoms get worse for 24 hours or more) and delayed disability progression (slowing down of the disease getting worse). The CLASSIC-MS study looked at the long-term effectiveness of treatment with cladribine tablets in people living with MS who had taken part in the original CLARITY and CLARITY Extension clinical studies. What were the results? Results showed that people treated with cladribine tablets maintained their mobility (the ability to move freely) for longer and experienced other positive effects long after their treatment ended, including being less likely to need further treatment for their MS. What do the results mean? The results obtained from CLASSIC-MS show that the benefits of taking cladribine tablets carry on even when patients stop taking the treatment.

引用

页码：261 / 268

页数：8

共 50 条

[21] Primary Results from 8-11 Years of Follow-up in the CLASSIC-MS Study Show Long-term Efficacy for Patients Who Received Cladribine Tablets in ORACLE MS
Leist, T.
Giovannoni, G.
Aydemir, A.
Di Cantogno, E. Verdun
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 69 - 69
[22] Effectiveness of cladribine tablets in the treatment of active relapsing-remitting multiple sclerosis: a multicenter, observational study
Habek, M.
Brecl, G. Jakob
Rajda, C.
Adamec, I.
Barun, B.
Rok, A.
Ledinek, A. Horvat
Rot, U.
Jazbec, S. Sega
Gabelic, T.
Klivenyi, P.
Skoric, M. Krbot
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 894 - 894
[23] Long-term management of multiple sclerosis patients treated with cladribine tablets: an expert opinion
Meuth, Sven G.
Bayas, Antonios
Kallmann, Boris
Kleinschnitz, Christoph
Linker, Ralf
Rieckmann, Peter
Maeurer, Mathias
EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (16) : 1965 - 1969
[24] Long-term efficacy for patients receiving cladribine tablets in CLARITY/CLARITY extension: Primary results from 9-15 years of follow-up in the CLASSIC-MS study
Giovannoni, G.
Leist, T.
Aydemir, A.
Di Cantogno, E. Verdun
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 792 - 793
[25] Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS)
Patti, Francesco
Visconti, Andrea
Capacchione, Antonio
Roy, Sanjeev
Trojano, Maria
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2020, 13
[26] Long-term follow-up of patients with a first clinical demyelinating event (clinically isolated syndrome) who received cladribine tablets in CLASSIC-MS: Findings for the ORACLE-MS cohort
Giovannoni, Gavin
Boyko, Alexey
Correale, Jorge
Edan, Gilles
Freedman, Mark S.
Montalban, Xavier
Rammohan, Kottil
Stefoski, Dusan
Yamout, Bassem
Leist, Thomas
Aydemir, Aida
Borsi, Laszlo
di Cantogno, Elisabetta Verdun
MULTIPLE SCLEROSIS JOURNAL, 2025, 31 (01) : 44 - 58
[27] Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study
Wiendl, Heinz
Barkhof, Frederik
Montalban, Xavier
Achiron, Anat
Derfuss, Tobias
Chan, Andrew
Hodgkinson, Suzanne
Prat, Alexandre
Leocani, Letizia
Schmierer, Klaus
Sellebjerg, Finn
Vermersch, Patrick
Jin, Hulin
Chudecka, Anita
Kloetgen, Andreas
Lin, Dongdong
Gardner, Lidia
De Stefano, Nicola
FRONTIERS IN IMMUNOLOGY, 2025, 16
[28] Long-term Real-world Safety and Efficacy of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis: The UAE Experience
Yamout, Bassem I.
Shatila, Ahmad
Inshasi, Jihad
Hassan, Ali Mohammed Ali
Szolics, Mikolas
Hassan, Ahmed
Farw, Ahmed
Ismail, Ghida
Zeineddine, Maya
MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 379 - 379
[29] Long-term Efficacy of Cladribine Tablets in Patients with Relapsing-Remitting or Secondary Progressive Multiple Sclerosis: Analysis of Real World Data From the Italian Multiple Sclerosis Registry (CLARINET-MS)
Patti, Francesco
Visconti, Andrea
Capacchione, Antonio
Trojano, Maria
NEUROLOGY, 2020, 94 (15)
[30] Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis
Leist, T.
Cook, S.
Comi, G.
Montalban, X.
Giovannoni, G.
Nolting, A.
Damian, D.
Syed, S.
Galazka, A.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 46

← 1 2 3 4 5 →